BioAge Labs is a biopharmaceutical company developing therapeutic candidates for metabolic and age-related diseases. The company employs a proprietary technology platform that analyzes molecular changes associated with aging to identify drug targets. This approach informs the development of its clinical-stage product portfolio, which currently includes azelaprag, an orally administered small molecule in phase 1 testing for obesity treatment, and a phase 2 combination study pairing azelaprag with tirzepatide in obese older adults. The company is also advancing BGE-102, a brain-penetrant oral small molecule targeting NLRP3 for neuroinflammatory diseases.
BioAge Labs operates as a clinical-stage biopharmaceutical firm with 62 full-time employees. The company is headquartered in Richmond, California and was incorporated in Delaware in 2015. As a pre-revenue or early-stage revenue company focused on clinical development, the firm has not yet commercialized approved products, and revenue generation remains dependent on the successful progression of its pipeline candidates through clinical trials and regulatory approval processes.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-6.63 | $-6.63 | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2024-12-31 | 2025-03-20 | 0000950170-25-042759 | SEC ↗ |